Page 4 - Life Sciences Vision News Today

Figures are a result of delays on new drugs, as study warns NHS appears 'uncomfortable with innovation'

Two major medical companies pull out of Britain’s official pricing scheme at a time of soaring demand for treatment

Angie Reynolds, head of Birmingham Research Park, at University of Birmingham Enterprise, explains why lab space is crucial for the support of medical technology innovation.

We have previously noted that 2023 may be a blockbuster year for European biotech deal making. A recent article in the Financial Times examines the…

Time between approval of a clinical trial to first dose of a drug being given to patients in Britain is more than eight months

Life Sciences Council Joint Statement on a new agreement to accelerate the delivery of the future UK HealthTech regulatory system.

UK medicines revenue clawback rockets to 26.5% putting Life Sciences Vision at risk, says ABPINext year manufacturers of branded medicines will be required to return almost £3.3bn in sales revenue to the government (26.5% of sales), up from around £0.6bn in 2021 and £1.8bn in 2022 [1].Company react...

Government announces funding to create the most advanced genomic healthcare system in the world, helping to save lives and improve health outcomes.

Red tape will be cut to speed up research into Motor Neurone Disease (MND) across the UK, enabling faster progress towards treatments.

NHS patients are set to benefit from cutting-edge new treatments and technologies as the government introduces a Vaccine Taskforce style approach to tackling some of the biggest public health challenges facing the UK.